HK1210434A1 - Pharmaceutical formulation containing thienotriazolodiazepine compounds - Google Patents
Pharmaceutical formulation containing thienotriazolodiazepine compoundsInfo
- Publication number
- HK1210434A1 HK1210434A1 HK15111309.6A HK15111309A HK1210434A1 HK 1210434 A1 HK1210434 A1 HK 1210434A1 HK 15111309 A HK15111309 A HK 15111309A HK 1210434 A1 HK1210434 A1 HK 1210434A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pharmaceutical formulation
- formulation containing
- thienotriazolodiazepine compounds
- containing thienotriazolodiazepine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261707465P | 2012-09-28 | 2012-09-28 | |
US201361782882P | 2013-03-14 | 2013-03-14 | |
US201361831811P | 2013-06-06 | 2013-06-06 | |
PCT/IB2013/003026 WO2014068402A2 (en) | 2012-09-28 | 2013-09-27 | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1210434A1 true HK1210434A1 (en) | 2016-04-22 |
Family
ID=50475880
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111309.6A HK1210434A1 (en) | 2012-09-28 | 2015-11-17 | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
HK15112002.4A HK1211209A1 (en) | 2012-09-28 | 2015-12-04 | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15112002.4A HK1211209A1 (en) | 2012-09-28 | 2015-12-04 | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
Country Status (13)
Country | Link |
---|---|
US (1) | US20140107107A1 (ru) |
EP (1) | EP2900221B1 (ru) |
JP (1) | JP2015531365A (ru) |
KR (1) | KR20150100613A (ru) |
CN (1) | CN104968334B (ru) |
AU (1) | AU2013340483B2 (ru) |
BR (1) | BR112015006537A2 (ru) |
CA (1) | CA2885944A1 (ru) |
HK (2) | HK1210434A1 (ru) |
IN (1) | IN2015DN03135A (ru) |
MX (1) | MX2015003771A (ru) |
RU (1) | RU2015115634A (ru) |
WO (1) | WO2014068402A2 (ru) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2569434B1 (en) | 2010-05-14 | 2019-09-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia and related disorders |
BR122014024883A2 (pt) | 2010-05-14 | 2019-08-20 | Dana-Farber Cancer Institute, Inc. | Compostos no tratamento de neoplasia |
US9266891B2 (en) * | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
UA119848C2 (uk) | 2013-03-15 | 2019-08-27 | Інсайт Холдинґс Корпорейшн | Трициклічні гетероцикли як інгібітори білків бет |
JP2016523964A (ja) | 2013-07-08 | 2016-08-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Betタンパク質阻害剤としての三環式複素環 |
US9795612B2 (en) | 2013-08-01 | 2017-10-24 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
WO2015018523A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A novel bet-brd inhibitor for treatment of solid tumors |
WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
KR20160037201A (ko) * | 2013-08-06 | 2016-04-05 | 온코에틱스 게엠베하 | Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법 |
WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
JP2016538310A (ja) * | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジアゼパン誘導体の使用 |
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
SG11201607108XA (en) | 2014-02-28 | 2016-09-29 | Tensha Therapeutics Inc | Treatment of conditions associated with hyperinsulinaemia |
LT3134403T (lt) | 2014-04-23 | 2020-05-11 | Incyte Corporation | 1h-pirolo[2,3-c]piridin-7(6h)-onai ir pirazolo[3,4-c]piridin-7(6h)-onai, kaip bet baltymų inhibitoriai |
CN107073014A (zh) * | 2014-05-02 | 2017-08-18 | 翁科埃斯克斯有限公司 | 利用噻吩并三唑并二氮杂*化合物治疗急性髓细胞白血病和/或急性淋巴细胞性白血病的方法 |
US20170095484A1 (en) * | 2014-05-02 | 2017-04-06 | Oncoethix Gmbh | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
WO2015168587A1 (en) * | 2014-05-02 | 2015-11-05 | Oncoethix Sa | Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds |
WO2015169953A1 (en) * | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
EP3139959A1 (en) | 2014-05-08 | 2017-03-15 | Oncoethix GmbH | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
EP3154549A1 (en) | 2014-06-13 | 2017-04-19 | Oncoethix GmbH | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
JP2017529332A (ja) * | 2014-08-28 | 2017-10-05 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬組成物を用いる急性骨髄性白血病又は急性リンパ性白血病の治療方法 |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
AU2015339511B2 (en) * | 2014-10-27 | 2020-05-14 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
KR102595599B1 (ko) | 2014-12-02 | 2023-11-02 | 이그니타, 인코포레이티드 | 신경모세포종의 치료를 위한 병용 |
WO2016176335A1 (en) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
PE20181086A1 (es) | 2015-09-11 | 2018-07-05 | Dana Farber Cancer Inst Inc | Acetamida tienotrizolodiazepinas y usos de las mismas |
CA2996974A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
EP3380100A4 (en) | 2015-11-25 | 2019-10-02 | Dana-Farber Cancer Institute, Inc. | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF |
WO2017106492A1 (en) | 2015-12-18 | 2017-06-22 | Ignyta, Inc. | Combinations for the treatment of cancer |
EP3192502A1 (en) * | 2016-01-15 | 2017-07-19 | Sandoz Ag | Pharmaceutical composition of selexipag |
WO2017121806A1 (en) * | 2016-01-15 | 2017-07-20 | Sandoz Ag | Pharmaceutical composition of selexipag |
EP3472157B1 (en) | 2016-06-20 | 2023-04-12 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
US10398693B2 (en) | 2017-07-19 | 2019-09-03 | Ignyta, Inc. | Pharmaceutical compositions and dosage forms |
CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
CN111629725A (zh) * | 2018-01-25 | 2020-09-04 | 勃林格殷格翰国际有限公司 | 急性骨髓性白血病的组合治疗 |
CN114727949A (zh) * | 2019-09-18 | 2022-07-08 | 百时美施贵宝公司 | Tyk2抑制剂的剂型 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022034914A1 (ja) * | 2020-08-13 | 2022-02-17 | カルナバイオサイエンス株式会社 | 易溶性固形製剤およびその製法 |
CN116098870B (zh) * | 2023-04-10 | 2023-07-25 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的固体分散体及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE227727T1 (de) * | 1996-09-13 | 2002-11-15 | Mitsubishi Pharma Corp | Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen |
KR100838686B1 (ko) | 2000-06-16 | 2008-06-16 | 미쯔비시 웰 파마 가부시키가이샤 | 방출 pH 범위 및/또는 속도 제어 조성물 |
CA2710740C (en) | 2007-12-28 | 2016-07-19 | Shinji Miyoshi | Thienotriazolodiazepine compound as antitumor agent |
EP2654726A4 (en) * | 2011-03-08 | 2013-10-30 | Zalicus Pharmaceuticals Ltd | SOLID DISPERSION FORMULATIONS AND METHODS OF USE |
-
2013
- 2013-09-27 BR BR112015006537A patent/BR112015006537A2/pt not_active Application Discontinuation
- 2013-09-27 WO PCT/IB2013/003026 patent/WO2014068402A2/en active Application Filing
- 2013-09-27 EP EP13848127.0A patent/EP2900221B1/en not_active Not-in-force
- 2013-09-27 IN IN3135DEN2015 patent/IN2015DN03135A/en unknown
- 2013-09-27 MX MX2015003771A patent/MX2015003771A/es unknown
- 2013-09-27 KR KR1020157009117A patent/KR20150100613A/ko not_active Application Discontinuation
- 2013-09-27 JP JP2015533717A patent/JP2015531365A/ja not_active Ceased
- 2013-09-27 RU RU2015115634A patent/RU2015115634A/ru unknown
- 2013-09-27 AU AU2013340483A patent/AU2013340483B2/en not_active Ceased
- 2013-09-27 CA CA2885944A patent/CA2885944A1/en not_active Abandoned
- 2013-09-27 US US14/040,134 patent/US20140107107A1/en not_active Abandoned
- 2013-09-27 CN CN201380061396.4A patent/CN104968334B/zh not_active Expired - Fee Related
-
2015
- 2015-11-17 HK HK15111309.6A patent/HK1210434A1/xx unknown
- 2015-12-04 HK HK15112002.4A patent/HK1211209A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BR112015006537A2 (pt) | 2017-07-04 |
WO2014068402A3 (en) | 2014-10-16 |
IN2015DN03135A (ru) | 2015-10-02 |
CA2885944A1 (en) | 2014-05-08 |
EP2900221A2 (en) | 2015-08-05 |
CN104968334A (zh) | 2015-10-07 |
US20140107107A1 (en) | 2014-04-17 |
RU2015115634A (ru) | 2016-11-20 |
WO2014068402A2 (en) | 2014-05-08 |
MX2015003771A (es) | 2016-03-04 |
AU2013340483A1 (en) | 2015-04-23 |
JP2015531365A (ja) | 2015-11-02 |
KR20150100613A (ko) | 2015-09-02 |
AU2013340483B2 (en) | 2018-01-18 |
HK1211209A1 (en) | 2016-05-20 |
EP2900221B1 (en) | 2019-03-06 |
CN104968334B (zh) | 2018-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211209A1 (en) | Pharmaceutical formulation containing thienotriazolodiazepine compounds | |
ZA201501930B (en) | Pharmaceutical composition | |
HK1203812A1 (en) | Novel pharmaceutical formulations | |
EP2931285A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
EP2832730A4 (en) | MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION | |
HK1205146A1 (en) | Pharmaceutical formulation | |
GB201205164D0 (en) | Pharmaceutical compounds | |
HK1205683A1 (en) | Pharmaceutical formulation having improved stability | |
HK1216619A1 (zh) | 藥物化合物 | |
ZA201502987B (en) | Pharmaceutical composition | |
PT2638894T (pt) | Composição farmacêutica com fosfolípido | |
PL2908836T3 (pl) | Formulacja farmaceutyczna zawierająca kurkuminę | |
EP2897590A4 (en) | PHARMACEUTICAL COMPOSITION | |
EP2883546A4 (en) | NOVEL DIFFERENTIALLY RELEASING PHARMACEUTICAL COMPOSITION CONTAINING THREE ACTIVE INGREDIENTS | |
SG11201406097SA (en) | Capsule formulation | |
GB201202027D0 (en) | Pharmaceutical compounds | |
HK1204945A1 (en) | Pharmaceutical formulation containing flupirtin | |
HK1209339A1 (en) | Pharmaceutical formulations | |
EP2851078A4 (en) | PHARMACEUTICAL COMPOSITION | |
GB201219236D0 (en) | Pharmaceutical compounds | |
GB201214121D0 (en) | Pharmaceutical compounds | |
GB201213519D0 (en) | Pharmaceutical compounds | |
GB201203253D0 (en) | Pharmaceutical compounds | |
ZA201400751B (en) | Pharmaceutical composition | |
GB201211403D0 (en) | Pharmaceutical formulations |